Comparator Sourcing for Clinical Trials Explained

Comparator sourcing is the work of finding, buying, documenting and supplying the reference medicine that a clinical trial compares against the investigational product. That reference can be an approved active drug, a placebo or the local standard of care. Good comparator sourcing for clinical trials delivers the right product version, in enough quantity, with enough shelf life and a documented supply history, to every site on time.

This guide is written for sponsors, CROs and clinical supply managers. It covers what counts as a comparator, the main sourcing routes, the decisions that drive cost and risk, the US and EU rules that apply, and how to assess comparator drug sourcing companies. The last section explains where transport, cold chain and customs clearance fit once the product has been sourced.

What is comparator sourcing?

Comparator sourcing is the process of identifying, procuring, qualifying and managing the supply of every product a trial uses as its reference arm. It starts with the protocol, which names the comparator, dose and regimen, and ends when the sites hold enough compliant, in-date stock for every enrolled patient. In between sit supplier selection, purchasing, documentation review, storage, any repackaging or blinding, labeling and distribution.

Regulators define the comparator broadly. ICH E6(R3), the current good clinical practice guideline, defines a comparator as an investigational or authorised medicinal product (an active control), a placebo or a standard of care used as a reference in a clinical trial. The EU Clinical Trials Regulation (EU) No 536/2014 goes a step further. It defines an investigational medicinal product as a product being tested or used as a reference, including as a placebo. In the EU a purchased comparator is therefore treated as an investigational medicinal product (IMP), even when it is an ordinary marketed medicine.

Comparators, reference products and auxiliary medicines

Comparator drug sourcing rarely covers one product only. Most sourcing plans include several categories, and each carries different rules.

The first category is the active comparator, an approved medicine given in the control arm and often the current standard of care for the indication. The second is placebo, an inactive product made to match the investigational product. It is manufactured rather than bought, but it belongs in the same supply plan. The third is standard of care, the treatment patients would normally receive, which can differ by country and is sometimes supplied by the sponsor to keep the arms consistent.

The fourth category is rescue and co-medication, meaning products given for the needs of the trial but not as the tested or reference product. The EU regulation calls these auxiliary medicinal products. Article 59 requires them to be authorised unless no authorised product is available in the EU or the sponsor cannot reasonably be expected to use one, and the protocol must justify that choice.

Concomitant medications that are unrelated to the trial design are outside this scope. Listing every category early prevents a common surprise, which is a rescue medicine that nobody budgeted for or a background therapy that is not marketed in one of the trial countries.

Why comparator sourcing matters for trial validity

Why is comparator sourcing important within clinical trials? Because the comparator arm is half of the evidence. If the comparator is the wrong formulation, an unapproved market version, expired or poorly stored, the comparison loses meaning and regulators may question the results. Sourcing also decides whether blinding can be maintained and whether sites receive stock before patients are randomized.

Three consequences follow from that. First, data integrity depends on the comparator matching the product described in the protocol and the clinical trial application. Second, regulatory acceptance depends on documentation, because inspectors and qualified persons need to see where the product came from and how it was handled. Third, patient safety and trial timelines depend on continuous supply, since a stock-out in the control arm can stop enrollment at a site as surely as a shortage of the investigational product.

In comparator sourcing, clinical trials depend on product quality as much as on price, so sourcing is a quality activity, not only a purchasing task. It connects to clinical supplies management more broadly, but it carries its own risks because the sponsor does not make the product and cannot control its commercial supply chain.

Comparator sourcing routes compared

Clinical trial comparator sourcing usually follows one of five routes, and many studies combine two or more. The table compares them on the criteria that matter most to a supply manager. It describes general tendencies, so check each route against the specific product and countries in your protocol.

The takeaway is that no route is best by default. Global comparator sourcing through one central market simplifies blinding and labeling, while local purchase can be the only workable option where a country restricts imports or requires the locally approved version. Strategic comparator sourcing means choosing the route per product and per country, then writing down why, so that the choice can be defended to regulators and revisited when supply changes.

What are the key aspects of comparator sourcing?

The key aspects of comparator sourcing are the product version, the lot strategy, shelf life, quantity, documentation and cost. Each one is a decision that should be made before the first purchase order, because changing it later usually means new paperwork and sometimes a protocol or application amendment.

Market version and country of origin

The same active ingredient can be sold as different products in different markets, with different strengths, excipients, pack sizes, labels and marketing authorizations. The protocol and clinical trial application name a specific product, so the version you buy must match. Record the source country, the authorization number and the manufacturer for every purchase. Where trial countries accept different versions, the regulatory team should confirm acceptance before purchasing rather than after the product arrives.

Single lot versus multiple lots

A single lot simplifies blinding, stability support, labeling and quality review. It is also harder to secure, because one lot must cover the full demand and remain in date for the whole study. Multiple lots are easier to buy but add documentation, increase the chance of mixed expiry dates at sites, and may require separate reference samples if the product is repackaged. Many sponsors aim for as few lots as practical rather than one lot at any cost.

Shelf life and expiry

Commercial products are bought with whatever shelf life remains when they leave the supplier. A comparator with short remaining shelf life can expire before the last patient finishes treatment. The EU guideline on good manufacturing practice for investigational medicinal products adds a further point. If a comparator is repackaged in a different container, the original expiry date may no longer apply, a justified retest date must be set by or on behalf of the sponsor, and that date must not be later than the original expiry date. Plan resupply windows around the shortest realistic shelf life, not the label date of the first delivery.

Quantity forecasting

Forecasting covers patients per arm, dose and titration, visit schedule, overage for damage and screening failures, site stock levels and the time it takes to resupply each country. Under-forecasting creates emergency buys at poor prices and mixed lots. Over-forecasting wastes expensive product and creates destruction work at the end of the study. Revisit the forecast as enrollment data comes in, especially for adaptive designs.

Cost

Comparator cost includes the purchase price, which can vary widely between markets, plus documentation, testing, repackaging or blinding, storage, transport, import duties and destruction of unused stock. A cheaper source can become the more expensive one if it adds import approvals, extra lots or longer lead times. Compare total landed cost per patient rather than unit price.

Regulatory and documentation requirements

The rules depend on where the comparator is bought, where it is modified and where it is used. The summaries below describe the US and EU frameworks as published by their regulators. Other countries apply their own rules, and the sponsor's regulatory team should confirm the position for each trial country.

United States

FDA states that an investigational drug imported for clinical studies must be covered by an investigational new drug application (IND) unless it is exempt under 21 CFR 312.2, and that the IND should be in place before import. Under 21 CFR 312.110, an imported investigational drug complies when an IND is in effect and the US consignee is the sponsor, a qualified investigator named in the IND, or the domestic agent of a foreign sponsor identified in the IND. FDA's page on importing investigational new drugs notes that entry documents are checked against the parties listed in the IND. If a comparator is a foreign market version rather than the US approved product, plan for it to be imported as an investigational drug and confirm the details with the FDA review division.

The immediate package of an investigational new drug must carry the caution statement set out in 21 CFR 312.6. Sponsors must also keep records of the receipt, shipment and disposition of investigational drugs under 21 CFR 312.57, including the investigator, date, quantity and batch or code mark of each shipment. For comparators bought inside the US commercial supply chain, the Drug Supply Chain Security Act sets an electronic, interoperable system to identify and trace certain prescription drugs at package level, so keep any tracing information the seller provides with the purchase record. Mercury's guide to DSCSA requirements for pharmaceutical shippers explains the shipping side.

European Union

Because the EU regulation treats a comparator as an IMP, its manufacture and import into the EU require an authorization under Article 61, and each batch must be certified by a qualified person (QP) under Article 62. Article 63 requires good manufacturing practice, and IMPs imported into the EU must be made to at least equivalent standards. Article 64 matters for comparators in particular. It applies the manufacturing, QP and GMP articles to authorised products only for modifications not covered by the marketing authorization, such as repackaging or over-encapsulation.

The detailed GMP rules sit in the Commission guideline of 8 December 2017 on good manufacturing practice for investigational medicinal products, which now occupies the Annex 13 slot of EudraLex Volume 4. It distinguishes sourcing scenarios. For a product bought on the EU open market that holds an EU marketing authorization, the QP certification can be limited to conformity with the trial authorization and to any blinding, trial-specific packaging and labeling. For a product imported directly from a third country, the QP must establish that equivalent GMP applies, through an operational mutual recognition agreement or, without one, normally through an audit of the manufacturer's quality system. This difference often decides whether EU-sourced or non-EU-sourced stock is more practical for a European study.

On labeling, Article 67 allows authorised IMPs to be labeled either under the trial labeling rules in Article 66 or under the normal marketing labeling rules, with additional trial particulars where the protocol requires them. The Regulation has applied since 31 January 2022.

Good clinical practice under ICH E6(R3)

ICH E6(R3) asks the sponsor to ensure that investigational products, including active controls and placebo, are manufactured under applicable GMP and coded and labeled to protect blinding. The sponsor should set acceptable storage temperatures, storage conditions and shelf life, package products to prevent deterioration during transport and storage, and keep records of identity, shipment, receipt, return and destruction. These expectations apply whatever the sourcing route.

The documents to collect

For each lot, the sourcing file should hold the certificate of analysis or batch release documentation where the supplier can provide it, the marketing authorization details, the supplier's license, purchase and transfer records that show the pedigree and chain of custody from manufacturer to depot, temperature records for every leg, and any import permits or licenses required by the destination. Where the comparator is repackaged or blinded, add the supporting data and the QP or sponsor release records. A lot that arrives without these documents can be hard or impossible to release, so secure them before payment.

Blinding and over-encapsulation

Comparator sourcing in clinical trials often feeds a blinding operation, because the comparator rarely looks like the investigational product. Common methods are over-encapsulation of tablets, repackaging into matching blisters or bottles, and matching placebo. Every modification creates new obligations. The EU IMP GMP guideline requires data, such as stability, comparative dissolution or bioavailability, showing that the change does not significantly alter the product's quality characteristics. It also requires a reference sample of the repackaged or over-encapsulated comparator to be retained, because the commercial retained sample does not represent the additional processing. Build the time for this work into the sourcing timeline, and buy enough extra product to support testing.

Cold chain, storage and shipment of comparators

Many comparators, especially biologics, need refrigerated or frozen storage, and all of them need documented conditions. The EU sponsor guideline on handling and shipping investigational medicinal products expects shipments to follow good distribution practice principles, equipment critical to holding temperature to be qualified, transport and storage temperatures to be monitored and evaluated at delivery, and deviations to be formally investigated with the manufacturer. It also states that the sponsor remains responsible for the IMP until the site or pharmacy receives and accepts it.

In practice that means agreeing the storage range on the comparator's approved label, choosing packaging qualified for the lane and season, sending a data logger with every shipment and keeping the records with the lot file. A comparator that has a temperature excursion in transit cannot be released to patients until quality has assessed it, so a single logistics failure can consume weeks of shelf life. Mercury's articles on end-to-end cold chain for clinical trials and on building clinical trial kits cover these steps in more detail.

Counterfeit and shortage risk

Comparators are bought in commercial markets, so they share the risks of those markets. WHO estimates that at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified, and defines falsified products as those that deliberately misrepresent their identity, composition or source, according to its fact sheet on substandard and falsified medical products. Buying only through manufacturers or licensed distributors, verifying documents and keeping an unbroken chain of custody are the main defenses.

Shortages are the second risk. A comparator can go on backorder, be discontinued in one market or be allocated by the manufacturer during the study. FDA publishes current and resolved shortages and discontinuations in its drug shortages database, and checking it, along with the equivalent lists in other trial countries, should be part of the sourcing assessment before the comparator is locked into the protocol.

Common challenges in comparator sourcing

What challenges can be identified in the comparator sourcing process? The recurring ones are limited supply, competitor reluctance to sell, short shelf life, mixed lots, missing documentation, country-specific import rules and the extra time needed for blinding. Most problems trace back to a sourcing decision made too late or without the full list of trial countries.

• Availability and allocation. The manufacturer may not sell in the volume or timeframe the study needs, or may restrict sales to certain channels.

• Documentation gaps. Distributors may not provide a certificate of analysis or full batch history, which can block QP certification or inspection readiness.

• Version mismatch. A product bought in one market may not be the version approved in a trial country.

• Expiry pressure. Remaining shelf life at purchase may be shorter than the treatment period, forcing resupply with new lots.

• Import and export barriers. Some countries can restrict export of locally sold medicines or require permits and local licenses for import, which adds lead time.

• Price volatility. Prices differ by market and can change during a long study, which undermines the original budget.

• Temperature and handling failures. Excursions during storage or transit can make an expensive lot unusable.

Mitigation follows the same pattern for each item. Involve the sourcing team when the protocol is drafted, identify a backup source and route for every product, secure documentation commitments before paying, and monitor stock and expiry by country as enrollment progresses.

How do you choose a comparator drug sourcing partner?

Choose a comparator drug sourcing partner by checking market access, documentation quality, regulatory capability and supply continuity before price. Comparator drug sourcing services range from pure procurement to combined sourcing, packaging, blinding, storage and distribution, so decide first which parts you want to keep in house. Then assess each candidate against the same checklist.

1. Market access. Can the partner buy the exact version you need in the source markets you are considering, and through which channels?

2. Supplier qualification. How does it qualify manufacturers and distributors, and can it show licenses for each supplier?

3. Documentation. Will it commit to providing certificates of analysis, batch release documents and a complete pedigree for every lot?

4. Regulatory knowledge. Does it understand IND import requirements in the US, QP certification and import rules in the EU, and the rules in your other trial countries?

5. Quality system. Can it share its GDP and, where relevant, GMP status, audit history and deviation handling process? Plan your own audit.

6. Lot and expiry management. How does it secure single or few lots, and how does it report remaining shelf life before purchase?

7. Cold chain capability. Can it store and ship at the product's labeled range with qualified equipment and complete temperature records?

8. Contingency. What is its plan for backorders, allocation or a discontinued product partway through the study?

9. Transparency on cost. Does the quote separate product price, fees, testing, storage and logistics so you can compare total landed cost?

Ask for references from studies of similar size and geography, and agree responsibilities in a quality agreement before the first order. When comparing comparator drug sourcing companies, the one with the lowest unit price is rarely the cheapest once delays, missing documents and replacement lots are counted.

Where logistics fits after sourcing

Once a comparator has been bought and released, it still has to move from the supplier to a depot or packager, across borders and on to sites, without losing temperature control or documentation. This is where Mercury comes in. Mercury's clinical trials logistics team moves comparators with GDP-compliant handling, cold chain packaging and real-time shipment visibility, across four temperature zones, from cryogenic shipping at -196°C and frozen transport between -20°C and -80°C to refrigerated shipping at 2 to 8°C and controlled room temperature at 15 to 25°C.

For cross-border movements, Mercury's licensed team provides customs brokerage and completes customs pre-advisory documentation before a cold chain shipment moves, so that entry paperwork is ready before the product reaches the border rather than after a hold. For the most time-critical lots, onboard couriers travel with the shipment on the next available flight and deliver it door to door. Planning these steps alongside the sourcing decision keeps the comparator usable from purchase to the patient.